Artesunate in the treatment of metastatic uveal melanoma - first experiences

Publication type:
Journal article
Metadata:
Autoren
  • TG Berger
  • D Dieckmann
  • T Efferth
  • ES Schultz
  • JO Funk
  • A Baur
  • G Schuler
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000233494200033&DestLinkType=FullRecord&DestApp=WOS_CPL
eISSN
1791-2431
Externe Identifier
  • Clarivate Analytics Document Solution ID: 987BU
  • PubMed Identifier: 16273263
ISSN
1021-335X
Ausgabe der Veröffentlichung
6
Zeitschrift
ONCOLOGY REPORTS
Schlüsselwörter
  • artesunate
  • artemisinin
  • melanoma
  • uvea
  • Dacarbazine
  • Fotemustine
  • chemotherapy
Paginierung
1599 - 1603
Datum der Veröffentlichung
2005
Status
Published
Titel
Artesunate in the treatment of metastatic uveal melanoma - first experiences
Sub types
  • Article
Ausgabe der Zeitschrift
14

Data source: Web of Science (Lite)

Other metadata sources:
Abstract
Artesunate (ART) is a derivative of artemisinin, the active principle of the Chinese herb Artemisia annua L. Artesunate is approved for the treatment of multidrug-resistant malaria and has an excellent safety profile. It has been shown that Artesunate, apart from its anti-malarial activity, has cytotoxic effects on a number of human cancer cell lines, including leukemia, colon cancer and melanoma. We report on the first long-term treatment of two cancer patients with ART in combination with standard chemotherapy. These patients with metastatic uveal melanoma were treated on a compassionate-use basis, after standard chemotherapy alone was ineffective in stopping tumor growth. The therapy-regimen was well tolerated with no additional side effects other than those caused by standard chemotherapy alone. One patient experienced a temporary response after the addition of ART to Fotemustine while the disease was progressing under therapy with Fotemustine alone. The second patient first experienced a stabilization of the disease after the addition of ART to Dacarbazine, followed by objective regressions of splenic and lung metastases. This patient is still alive 47 months after first diagnosis of stage IV uveal melanoma, a situation with a median survival of 2-5 months. Despite the small number of treated patients, ART might be a promising adjuvant drug for the treatment of melanoma and possibly other tumors in combination with standard chemotherapy. Its good tolerability and lack of serious side effects will facilitate prospective randomized trials in the near future.
Addresses
  • Department of Dermatology, University Hospital of Erlangen, Erlangen, Germany. thomas.berger@derma.imed.uni-erlangen.de
Autoren
  • Thomas G Berger
  • Detlef Dieckmann
  • Thomas Efferth
  • Erwin S Schultz
  • Jens-Oliver Funk
  • Andreas Baur
  • Gerold Schuler
eISSN
1791-2431
Externe Identifier
  • PubMed Identifier: 16273263
Open access
false
ISSN
1021-335X
Ausgabe der Veröffentlichung
6
Zeitschrift
Oncology reports
Schlüsselwörter
  • Humans
  • Artemisia
  • Melanoma
  • Liver Neoplasms
  • Uveal Neoplasms
  • Lung Neoplasms
  • Sesquiterpenes
  • Artemisinins
  • Dacarbazine
  • Antineoplastic Combined Chemotherapy Protocols
  • Treatment Outcome
  • Fatal Outcome
  • Time Factors
  • Aged
  • Female
  • Male
  • Artesunate
Sprache
eng
Medium
Print
Paginierung
1599 - 1603
Datum der Veröffentlichung
2005
Status
Published
Datum der Datenerfassung
2005
Titel
Artesunate in the treatment of metastatic uveal melanoma--first experiences.
Sub types
  • Journal Article
  • Case Reports
Ausgabe der Zeitschrift
14

Data source: Europe PubMed Central

Abstract
Artesunate (ART) is a derivative of artemisinin, the active principle of the Chinese herb Artemisia annua L. Artesunate is approved for the treatment of multidrug-resistant malaria and has an excellent safety profile. It has been shown that Artesunate, apart from its anti-malarial activity, has cytotoxic effects on a number of human cancer cell lines, including leukemia, colon cancer and melanoma. We report on the first long-term treatment of two cancer patients with ART in combination with standard chemotherapy. These patients with metastatic uveal melanoma were treated on a compassionate-use basis, after standard chemotherapy alone was ineffective in stopping tumor growth. The therapy-regimen was well tolerated with no additional side effects other than those caused by standard chemotherapy alone. One patient experienced a temporary response after the addition of ART to Fotemustine while the disease was progressing under therapy with Fotemustine alone. The second patient first experienced a stabilization of the disease after the addition of ART to Dacarbazine, followed by objective regressions of splenic and lung metastases. This patient is still alive 47 months after first diagnosis of stage IV uveal melanoma, a situation with a median survival of 2-5 months. Despite the small number of treated patients, ART might be a promising adjuvant drug for the treatment of melanoma and possibly other tumors in combination with standard chemotherapy. Its good tolerability and lack of serious side effects will facilitate prospective randomized trials in the near future.
Autoren
  • Thomas G Berger
  • Detlef Dieckmann
  • Thomas Efferth
  • Erwin S Schultz
  • Jens-Oliver Funk
  • Andreas Baur
  • Gerold Schuler
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/16273263
ISSN
1021-335X
Ausgabe der Veröffentlichung
6
Zeitschrift
Oncol Rep
Schlüsselwörter
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Artemisia
  • Artemisinins
  • Artesunate
  • Dacarbazine
  • Fatal Outcome
  • Female
  • Humans
  • Liver Neoplasms
  • Lung Neoplasms
  • Male
  • Melanoma
  • Sesquiterpenes
  • Time Factors
  • Treatment Outcome
  • Uveal Neoplasms
Sprache
eng
Country
Greece
Paginierung
1599 - 1603
Datum der Veröffentlichung
2005
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2006
Titel
Artesunate in the treatment of metastatic uveal melanoma--first experiences.
Sub types
  • Case Reports
  • Journal Article
Ausgabe der Zeitschrift
14

Data source: PubMed

Beziehungen:
Property of

Tools